[
  {
    "ts": null,
    "headline": "Gilead’s HIV Advances And Yescarta Label Shift Refocus Investment Thesis",
    "summary": "Gilead Sciences (NasdaqGS:GILD) plans to present late breaking data at CROI 2026 on a new investigational single tablet HIV regimen. The company will also share the first HIV cure clinical program data from South Africa at the same conference. Kite, Gilead's cell therapy unit, supported the largest metabolomic study in CAR T cell therapy to date. The FDA updated the label for Yescarta, removing major use limitations for the CAR T cell therapy. For investors tracking Gilead, these updates...",
    "url": "https://finnhub.io/api/news?id=39afd4d9fad9a2845dbd33d11b6235fb285c106a19422ca431b33c27e8993d71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771344697,
      "headline": "Gilead’s HIV Advances And Yescarta Label Shift Refocus Investment Thesis",
      "id": 139125130,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NasdaqGS:GILD) plans to present late breaking data at CROI 2026 on a new investigational single tablet HIV regimen. The company will also share the first HIV cure clinical program data from South Africa at the same conference. Kite, Gilead's cell therapy unit, supported the largest metabolomic study in CAR T cell therapy to date. The FDA updated the label for Yescarta, removing major use limitations for the CAR T cell therapy. For investors tracking Gilead, these updates...",
      "url": "https://finnhub.io/api/news?id=39afd4d9fad9a2845dbd33d11b6235fb285c106a19422ca431b33c27e8993d71"
    }
  },
  {
    "ts": null,
    "headline": "Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ",
    "summary": "While the S&P 500 (NYSEARCA:SPY) sits flat year-to-date, the Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) has surged nearly 7%. This shift reflects growing concerns about expensive technology valuations and concentration risk, with the Magnificent Seven trading above 30x earnings on average while comprising over 30% of the S&P 500. COWZ addresses a specific portfolio ... Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ",
    "url": "https://finnhub.io/api/news?id=d5bd9ac1b35f498290776c12d5b03c7cbd67de07e162744769e89bacda422f85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771337008,
      "headline": "Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ",
      "id": 139123938,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "While the S&P 500 (NYSEARCA:SPY) sits flat year-to-date, the Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) has surged nearly 7%. This shift reflects growing concerns about expensive technology valuations and concentration risk, with the Magnificent Seven trading above 30x earnings on average while comprising over 30% of the S&P 500. COWZ addresses a specific portfolio ... Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ",
      "url": "https://finnhub.io/api/news?id=d5bd9ac1b35f498290776c12d5b03c7cbd67de07e162744769e89bacda422f85"
    }
  },
  {
    "ts": null,
    "headline": "Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity",
    "summary": "Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced its industry-leading global metabolomics platform was used by researchers from Kite, a Gilead company, for the most extensive metabolomic study ever conducted in the context of CAR T-cell therapy. Leveraging Metabolon's untargeted Global Discovery Panel, Kite researchers analyzed more th",
    "url": "https://finnhub.io/api/news?id=0d06f1989ddd3167fff11e0386537ea8bf48b35b560e4efde0d91db3c7bab02b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771336800,
      "headline": "Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity",
      "id": 139124034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced its industry-leading global metabolomics platform was used by researchers from Kite, a Gilead company, for the most extensive metabolomic study ever conducted in the context of CAR T-cell therapy. Leveraging Metabolon's untargeted Global Discovery Panel, Kite researchers analyzed more th",
      "url": "https://finnhub.io/api/news?id=0d06f1989ddd3167fff11e0386537ea8bf48b35b560e4efde0d91db3c7bab02b"
    }
  },
  {
    "ts": null,
    "headline": "Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options",
    "summary": "FOSTER CITY, Calif., February 17, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities affected by HIV, notable late-breaking abstr",
    "url": "https://finnhub.io/api/news?id=5cf4c272143ab0d0637f0b3eabff82f4e4035d6cb21dabd731fa80e73df9912d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771335000,
      "headline": "Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options",
      "id": 139122176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., February 17, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities affected by HIV, notable late-breaking abstr",
      "url": "https://finnhub.io/api/news?id=5cf4c272143ab0d0637f0b3eabff82f4e4035d6cb21dabd731fa80e73df9912d"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call",
    "summary": "Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market responded negatively as investors focused on guidance and margin pressures. Management cited strong growth in its HIV business, including a 53% increase in the HIV prevention portfolio and rapid uptake of the new YES2GO injectable, as key drivers. CEO Daniel O’Day noted, “YES2GO is a transformative medicine that we expect to drive durable, steady, and long-term growth in our HIV p",
    "url": "https://finnhub.io/api/news?id=0c4454925fb97e53fc6afa99f1dad11b222ad1c95ff766c3caf684490d61f5bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771306325,
      "headline": "5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call",
      "id": 139122177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market responded negatively as investors focused on guidance and margin pressures. Management cited strong growth in its HIV business, including a 53% increase in the HIV prevention portfolio and rapid uptake of the new YES2GO injectable, as key drivers. CEO Daniel O’Day noted, “YES2GO is a transformative medicine that we expect to drive durable, steady, and long-term growth in our HIV p",
      "url": "https://finnhub.io/api/news?id=0c4454925fb97e53fc6afa99f1dad11b222ad1c95ff766c3caf684490d61f5bc"
    }
  }
]